Vivos Inc (RDGL)

[bdvest]

Another great result of Y-90 in Human cancer treatment
Radiogel has its unique features, it is much better delivery approach which immobilized in place with much less harm to normal tissue, it will be approved in human clinic usage!!!

Am J Surg. 2018 Mar;215(3):467-470. doi: 10.1016/j.amjsurg.2017.11.022. Epub 2018 Feb 2.
Is there a role for Ytrrium-90 in the treatment of unresectable and metastatic intrahepatic cholangiocarcinoma?
Shaker TM1, Chung C2, Varma MK3, Doherty MG3, Wolf AM4, Chung MH4, Assifi MM5.
Author information
Abstract
BACKGROUND:
Selective internal radiation therapy (SIRT) with Ytrrium-90 (Y-90) has been used to treat hepatic malignancies with success. This study focuses on the efficacy and safety of Y-90 in the treatment of unresectable and metastatic intrahepatic cholangiocarcinoma (ICC).

METHODS:
A single-institution retrospective case review was performed for patients with unresectable and metastatic ICC treated with Y-90 between 2006 and 2016.

RESULTS:
Seventeen patients with ICC underwent 21 Y-90 treatments. Four patients had undergone prior liver resection, and six patients had extrahepatic disease at the time of treatment. Five year overall survival was 26.8%, with a median survival of 33.6 months. One patient underwent margin negative liver resection after a single treatment. Complications were appreciated in two cases. Ninety-day mortality was 0%.

CONCLUSION:
Treatment of ICC using Y-90 is a safe and promising procedure. Further research is needed to clarify its role in the treatment of unresectable and metastatic ICC.